Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 12:40 AM
Ignite Modification Date:
2025-12-25 @ 12:40 AM
NCT ID:
NCT01149967
Brief Summary:
This is a bioequivalence study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited under fasting conditions.
Detailed Description:
randomized, 2-way crossover; bioequivalence study of citalopram hydrobromide 40mg tablets and celexa 40 mg tablets administered as
1 x 40 mg tablet in healthy subjects under fasting conditions
Study:
NCT01149967
Study Brief:
Protocol Section:
NCT01149967